BlackRock Fund Advisors’s Ocular Therapeutix OCUL Stock Holding History

BlackRock Fund Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.81M	Sell	574,555 -249,871	-30%	-$1.94M	﹤0.01%	2956
2016 Q3	$5.66M	Buy	824,426 +48,815	+6%	+$298K	﹤0.01%	2790
2016 Q2	$3.84M	Buy	775,611 +71,882	+10%	+$712K	﹤0.01%	2954
2016 Q1	$6.8M	Buy	703,729 +10,320	+1%	+$78.2K	﹤0.01%	2575
2015 Q4	$6.5M	Buy	693,409 +300,956	+77%	+$3.25M	﹤0.01%	2689
2015 Q3	$5.52M	Buy	392,453 +47,117	+14%	+$947K	﹤0.01%	2747
2015 Q2	$7.26M	Buy	345,336 +183,236	+113%	+$4.54M	﹤0.01%	2691
2015 Q1	$6.81M	Buy	162,100 +4,361	+3%	+$143K	﹤0.01%	2664
2014 Q4	$3.71M	Buy	157,739 +16,177	+11%	+$272K	﹤0.01%	3017
2014 Q3	$2.12M	Buy	+141,562	New	+$2.09M	﹤0.01%	3114

Other funds holding OCUL

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock Fund Advisors's OCUL Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Ocular Therapeutix (OCUL) stake by 30% in Q4 2016, selling an estimated $1.94M and leaving 574,555 shares worth $4.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2956.

BlackRock Fund Advisors first reported a position in OCUL in Q3 2014 and has held it in 10 quarters since. The position peaked at $7.26M in Q2 2015. 76 funds tracked by Wall St. Rank hold OCUL as of Q4 2016.

BlackRock Fund Advisors held 574,555 shares of Ocular Therapeutix worth $4.81M as of Q4 2016.
BlackRock Fund Advisors sold 249,871 Ocular Therapeutix shares in Q4 2016, an estimated $1.94M.
Ocular Therapeutix made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2956 holding.
BlackRock Fund Advisors first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 10 quarters since.
BlackRock Fund Advisors's Ocular Therapeutix position peaked at $7.26M in Q2 2015.
76 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.